The estimated Net Worth of Pablo J Cagnoni is at least $1.73 Million dollars as of 1 February 2023. Pablo Cagnoni owns over 8,448 units of Rubius Therapeutics Inc stock worth over $5,485 and over the last 8 years he sold RUBY stock worth over $2,112. In addition, he makes $1,721,130 as President, Chief Executive Officer, and Director at Rubius Therapeutics Inc.
Sign up
Pablo Cagnoni RUBY stock SEC Form 4 insiders trading
Pablo has made over 8 trades of the Rubius Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 8,448 units of RUBY stock worth $2,112 on 1 February 2023.
The largest trade he's ever made was exercising 46,250 units of Rubius Therapeutics Inc stock on 29 January 2023 worth over $3,839. On average, Pablo trades about 4,883 units every 64 days since 2016. As of 1 February 2023 he still owns at least 66,082 units of Rubius Therapeutics Inc stock.
You can see the complete history of Pablo Cagnoni stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Pablo Cagnoni biography
Dr. Pablo J. Cagnoni M.D. serves as President, Chief Executive Officer, Director of the Company. He joined Tizona as the company's first employee and grew the organization to support the filing of its first Investigational New Drug application. Prior to Tizona, he served as President of Onyx Pharmaceuticals, Inc. (acquired by Amgen), where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. Dr. Cagnoni joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen subsidiary. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology, where he was responsible for all clinical development, clinical operations, clinical pharmacology, and correlative sciences activities for the oncology development pipeline. From 2007 to 2009, Dr. Cagnoni was Senior Vice President and Chief Medical Officer at Allos Therapeutics, Inc. (acquired by Spectrum Pharmaceuticals) and, prior to that, Chief Medical Officer of OSI Pharmaceuticals, Inc. (acquired by Astellas). Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program, where he cared for patients undergoing stem cell transplants. Dr. Cagnoni earned his medical degree from the University Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology at the Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center. Cagnoni's perspective and experience serving as our Chief Executive Officer and extensive experience supporting the development of therapeutics qualify him to serve on our board of directors.
What is the salary of Pablo Cagnoni?
As the President, Chief Executive Officer, and Director of Rubius Therapeutics Inc, the total compensation of Pablo Cagnoni at Rubius Therapeutics Inc is $1,721,130. There are no executives at Rubius Therapeutics Inc getting paid more.
How old is Pablo Cagnoni?
Pablo Cagnoni is 57, he's been the President, Chief Executive Officer, and Director of Rubius Therapeutics Inc since 2020. There are 10 older and 7 younger executives at Rubius Therapeutics Inc. The oldest executive at Rubius Therapeutics Inc is Michael Rosenblatt, 69, who is the Independent Director.
What's Pablo Cagnoni's mailing address?
Pablo's mailing address filed with the SEC is 1801 AUGUSTINE CUT-OFF, , WILMINGTON, DE, 19083.
Insiders trading at Rubius Therapeutics Inc
Over the last 6 years, insiders at Rubius Therapeutics Inc have traded over $2,165,279 worth of Rubius Therapeutics Inc stock and bought 305,000 units worth $6,624,680 . The most active insiders traders include Noubar Afeyan, Roger Pomerantz, and Robert Langer. On average, Rubius Therapeutics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $2,709. The most recent stock trade was executed by Dannielle Appelhans on 24 February 2023, trading 10,385 units of RUBY stock currently worth $1,350.
What does Rubius Therapeutics Inc do?
developing a novel enucleated cell (ecell)(tm) therapy platform for unmet medical needs. founded by flagship venturelabs.
What does Rubius Therapeutics Inc's logo look like?
Complete history of Pablo Cagnoni stock trades at CRISPR Therapeutics AG, Incyte, Rubius Therapeutics Inc, and Fusion Pharmaceuticals
Rubius Therapeutics Inc executives and stock owners
Rubius Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Pablo Cagnoni,
President, Chief Executive Officer, Director -
Maiken Keson-Brookes,
Chief Legal Officer, Corporate Secretary -
Dr. Pablo J. Cagnoni M.D., Ph.D.,
CEO, Pres & Director -
David Epstein,
Chairman of the Board -
Laurence A. Turka M.D.,
Chief Scientific Officer and Head of Research & Translational Medicine -
Natalie Holles,
Independent Director -
David R. Epstein B.Sc., M.B.A.,
Exec. Chairman -
Dannielle Appelhans,
Chief Operating Officer -
Anne Prener,
Independent Director -
Jonathan Symonds,
Independent Director -
Francis Cuss,
Independent Director -
Catherine Sohn,
Independent Director -
Noubar Afeyan,
Independent Director -
Michael Rosenblatt,
Independent Director -
Lori Melancon,
IR Contact Officer -
Christina Coughlin,
Chief Medical Officer -
Greg ..,
Chief Quality Officer -
Laurence Turka,
Chief Scientific Officer -
Kris Elverum,
Senior Vice President - Business Development and Strategy -
Jose Carmona,
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer -
Jill Murray,
VP & Head of HR -
Marissa Hanify,
Director of Corp. Communications -
Maiken Keson-Brookes,
Chief Legal Officer & Corp. Sec. -
Elhan Webb C.F.A.,
VP of Investor Relations -
Mark J. Hernon,
Chief Information Officer -
Spencer Fisk,
Sr. VP & Chief Technical Operations Officer -
Jose I. Carmona,
CFO, Principal Accounting Officer & Treasurer -
Ventures Fund Iv General Pa...,
-
Susanne Schaffert,
Director -
Robert Langer,
Director -
Roger Pomerantz,
Director -
Ventures Fund Iv General Pa...,
-
Torben Straight Nissen,
President -
Christopher L. Carpenter,
Chief Medical Officer -
Dannielle Appelhans,
CEO and President